Introduction to sample size determination and power analysis for clinical trials.
about
S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]A comparison of respirator fit factors determined by portable condensation nuclei counting and forward light-scattering photometric methodsTopical treatments for cutaneous wartsSORL1 variants and risk of late-onset Alzheimer's diseaseThe fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?Metabolic modeling with Big Data and the gut microbiomeCoagulopathy and transfusion strategies in trauma. Overwhelmed by literature, supported by weak evidenceOpportunities and limitations of SELDI-TOF-MS in biomedical research: practical advicesProphylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover studyEfficacy of the acyclic guanosine analog buciclovir [(R)-9-(3,4-dihydroxybutyl)guanine] in experimental genital herpesSample size calculations for prevalent cohort designsInternet-delivered cognitive-behavioural therapy for concerned significant others of people with problem gambling: study protocol for a randomised wait-list controlled trialCase-based Learning Outperformed Simulation Exercises in Disaster Preparedness Education Among Nursing Trainees in India: A Randomized Controlled Trial.Did modeling overestimate the transmission potential of pandemic (H1N1-2009)? Sample size estimation for post-epidemic seroepidemiological studiesDesign and conduct of the CALERIE study: comprehensive assessment of the long-term effects of reducing intake of energyFetal echocardiography for congenital heart disease diagnosis: a meta-analysis, power analysis and missing data analysis.How effective is tetracaine 4% gel, before a peripherally inserted central catheter, in reducing procedural pain in infants: a randomized double-blind placebo controlled trial [ISRCTN75884221].Sequelae of haemolytic uraemic syndrome.Are migraineur women really more vulnerable to stress and less able to cope?Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)Pragmatic versus explanatory trials.Influence of eye biometrics and corneal micro-structure on noncontact tonometry.HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans.Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sicknessIn vivo interaction of ketoconazole and sucralfate in healthy volunteersMinimally invasive endoscopic staging for mediastinal lymphadenopathy in lung cancer: a systematic review protocol.Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.Clinical research: the pharmaceutical industry's point of viewProspective 5-year postoperative study of cataract extraction and lens implantationAn analysis of corneal endothelial and graft survival in pseudophakic bullous keratopathyEffects of individual physician-level and practice-level financial incentives on hypertension care: a randomized trial.Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study.Choosing a pediatric recipient for orthotopic liver transplantation.Applications of the Wei-Lachin multivariate one-sided test for multiple outcomes on possibly different scales.Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.Limit allogeneic blood use with routine re-use of patient's own blood: a prospective, randomized, controlled trial in total hip surgeryAntipyrine clearance and metabolism in patients with psoriasis.Optimizing area under the ROC curve using semi-supervised learningDoes the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.Direct relationship between mononuclear leukocyte and lung beta-adrenergic receptors and apparent reciprocal regulation of extravascular, but not intravascular, alpha- and beta-adrenergic receptors by the sympathochromaffin system in humans.
P2860
Q21093296-C80C3CA8-E1EC-4210-BFEE-963D895BC96CQ23915084-DB909C79-C121-44BA-8370-0DEC947DA50CQ24200667-C6036E3D-EF6E-4215-B09A-A633F256A745Q24289419-69954B41-E81E-4596-A886-D9144D489D69Q24804857-DE53E200-75D8-4131-80DC-4D69A0773D2DQ28078364-B9595A82-F433-4F67-AC6E-19FEFB000706Q28082573-B9ADD176-EE0B-4C0B-8479-447676DBA694Q28287384-C47DA812-ED60-4756-811C-EAB815640EF5Q28345604-DC418AD1-4D49-4845-8618-BD32ABC5EB2FQ28360403-0A394C0B-2D36-4A6C-8A32-E8A432BBA3C8Q28387309-88151384-07F2-4382-94F3-02C20B3CC624Q28604180-F6150A7C-35DF-45AE-A588-8B5AC053F3A0Q30151865-51E4265B-7601-42BF-968D-6B6C60FAD6E9Q30401351-73355B3F-9FC4-4536-9CAD-E86D39E02347Q30498074-2F5F76C0-EA9A-45D5-AEF0-54BCDEE8C538Q30855324-C71B9ADF-F192-4185-9C43-2419F89DCADEQ33242106-9EDD55C2-CEB0-4764-95B7-B18587A755F5Q33361289-2B49221F-3B62-43A6-ABBA-5D6EAB82C3F0Q33375189-9769B6DC-9FA2-450C-B2D8-AF482DE544B1Q33387427-A832FC2D-18C9-460B-BC15-7D05A32CB827Q33630113-95B7015E-C7AD-4B5C-98C3-16F1206B2470Q33638194-8C17C703-70EF-480B-A889-00B9749E7D4AQ33690850-D3EBDE66-0186-4415-9307-DFF2ED05E899Q33748367-9EEEDA36-F139-4103-A204-1806F1479CE3Q33749319-ECDD1366-A041-4044-A307-026E347DB6CDQ33995852-EA89111E-A9EA-41EB-A001-A94A20D7A0ADQ34079225-A0942AE5-8732-4003-AD27-222AF0D31200Q34137737-76DD83C9-AD08-47D1-ACCF-89F3DB440AD6Q34164202-DF5DEB44-5481-4021-AAB2-10F059D823A9Q34164354-00B4BA3A-89B1-400C-B1F3-A11905943291Q34194559-90FBE59B-E52A-4CC8-A33B-DB79AFF241B1Q34198365-2BC7B413-BAFF-4A70-A5F5-1969A0D69E61Q34240993-115372F5-F5EA-49B6-AD9F-2D110EB6269AQ34361859-F9A085DF-1401-49DB-AC75-28138106C815Q34397841-DCA944FA-728C-48EF-B7E0-D3E7D190282FQ34427128-15ED2043-252C-41BD-B3B5-77F74604DBB1Q34448073-A6C60ECC-2F46-4854-B41C-487F5FFBAB81Q34482907-4C4120BE-CE68-442E-BC67-7A8D51822A2DQ34549363-B6448DD2-BDBB-4F0A-AEB2-A0A458AA5803Q34556465-7D07C4EB-45DD-454A-9C47-A2F9F890D000
P2860
Introduction to sample size determination and power analysis for clinical trials.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
Introduction to sample size determination and power analysis for clinical trials.
@en
Introduction to sample size determination and power analysis for clinical trials.
@nl
type
label
Introduction to sample size determination and power analysis for clinical trials.
@en
Introduction to sample size determination and power analysis for clinical trials.
@nl
prefLabel
Introduction to sample size determination and power analysis for clinical trials.
@en
Introduction to sample size determination and power analysis for clinical trials.
@nl
P1476
Introduction to sample size determination and power analysis for clinical trials.
@en
P304
P356
10.1016/0197-2456(81)90001-5
P407
P577
1981-06-01T00:00:00Z